GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data

DOJ press release 12-842 (2 July 2012), GSK $3 billion resolution: criminal plea ($1 billion: fine $956,814,400, forfeiture $43,185,600; Paxil/Wellbutrin $757,387,200; Avandia $242,612,800); civil settlements: off-label and kickbacks $1.043 billion (federal $832 million, states $210 million) resolving four qui tam suits in D. Mass.; Avandia $657 million (federal $508 million, states $149 million) and price reporting $300 million ($160,972,069 federal, $118,792,931 states, $20,235,000 Public Health Service entities), neither linked to a qui tam suit in the release; corporate integrity agreement; HEAT: more than $10.2 billion over three years in health care fraud under the FCA and the FDCA combined (fines and forfeiture included, so not an FCA recovery figure; not recorded). No relator share is printed. Already in the data: 1 case and 1 event. Nothing added (the off-label qui tam settlement is now also a case from the settlement agreement itself). Same release as usa-doj-pr-gsk-2012 (another capture); both already have a case row for the same resolution.